Stay updated on Effect of Oral AT1001 in Fabry Disease Clinical Trial
Sign up to get notified when there's something new on the Effect of Oral AT1001 in Fabry Disease Clinical Trial page.

Latest updates to the Effect of Oral AT1001 in Fabry Disease Clinical Trial page
- CheckyesterdayChange DetectedThe page has removed a citation regarding the assessment of plasma lyso-Gb3 for clinical monitoring in Fabry disease, which included an erratum reference.SummaryDifference0.3%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to include new information about Fabry Disease and the study AT1001-011 FACETS, while significant details about the study's objectives, methodology, and participant criteria have been removed.SummaryDifference20%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Effect of Oral AT1001 in Fabry Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Effect of Oral AT1001 in Fabry Disease Clinical Trial page.